Abstract
AbstractChimeric antigen receptor (CAR)-T cells (CART) remain one of the most advanced and promising forms of adoptive T-cell immunotherapy. CART represent autologous, genetically engineered T lymphocytes expressing CAR, i.e. fusion proteins that combine components and features of T cells as well as antibodies providing their more effective and direct anti-tumour effect. The technology of CART construction is highly advanced in vitro and every element of their structure influence their mechanism of action in vivo. Patients with haematological malignancies are faced with the possibility of disease relapse after the implementation of conventional chemo-immunotherapy. Since the most preferable result of therapy is a partial or complete remission, cancer treatment regimens are constantly being improved and customized to individual patients. This individualization could be ensured by CART therapy. This paper characterized CART strategy in details in terms of their structure, generations, mechanism of action and published the results of clinical trials in haematological malignancies including acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and multiple myeloma.
Funder
Uniwersytet Medyczny w Lublinie
Medical University of Lublin
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Immunology,Immunology and Allergy
Reference144 articles.
1. Abramson JS, Gordon LI, Palomba ML et al (2018a) Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol 36:7505–7505. https://doi.org/10.1200/JCO.2018.36.15_suppl.7505
2. Abramson JS, Siddiqi T, Palomba ML et al (2018b) High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): a defined composition CD19-directed CAR T-cell product with potential for outpatient administration. J Clin Oncol 36:120–120. https://doi.org/10.1200/JCO.2018.36.5_suppl.120
3. Abramson JS, Palomba LM, Gordon LI et al (2020) Safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Transplantation and cellular therapy meetings, February 19–23, 2020, Orlando, Florida
4. Ali SA, Shi V, Maric I et al (2016) T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128:1688–1700. https://doi.org/10.1182/blood-2016-04-711903
5. Bagley S, Hawkins RE, Gilham DE et al (2010) The optimal antigen response of chimeric antigen receptors harboring the CD3 transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol 184:6938–6949. https://doi.org/10.4049/jimmunol.0901766
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献